Osteopore signs a major China distribution deal, but risks remain
Osteopore (ASX: OSX) surged 71 per cent last Friday after announcing an exclusive distribution deal with Majeton Limited valued at…
Investors should expect to see more ASX biotechs focus on Asia in the years ahead. And there are good reasons why.
For many companies, the golden market has been the USA,…